Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Significantly higher rates of multiple and proximally located adenomas among patients with diabetes mellitus: A cross-sectional population-based study.

de Kort S, Bouwens MW, Weijenberg MP, Janssen-Heijnen ML, de Bruïne AP, Riedl R, Masclee AA, Sanduleanu S.

United European Gastroenterol J. 2017 Apr;5(3):415-423. doi: 10.1177/2050640616664271. Epub 2016 Aug 9.

2.

Diabetes mellitus type 2 and subsite-specific colorectal cancer risk in men and women: results from the Netherlands Cohort Study on diet and cancer.

de Kort S, Simons CC, van den Brandt PA, Goldbohm RA, Arts IC, de Bruine AP, Janssen-Heijnen ML, Sanduleanu S, Masclee AA, Weijenberg MP.

Eur J Gastroenterol Hepatol. 2016 Aug;28(8):896-903. doi: 10.1097/MEG.0000000000000626.

PMID:
27097356
3.

The emerging role of GATA transcription factors in development and disease.

Lentjes MH, Niessen HE, Akiyama Y, de Bruïne AP, Melotte V, van Engeland M.

Expert Rev Mol Med. 2016 Mar 8;18:e3. doi: 10.1017/erm.2016.2. Review.

4.

The relevance of pathological verification in suspected pancreatic cancer.

Bernards N, Creemers GJ, Huysentruyt CJ, de Hingh IH, van der Schelling GP, de Bruïne AP, Lemmens VE.

Cancer Epidemiol. 2015 Apr;39(2):250-5. doi: 10.1016/j.canep.2015.01.004. Epub 2015 Feb 7.

PMID:
25670054
5.

CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.

Cleven AH, Derks S, Draht MX, Smits KM, Melotte V, Van Neste L, Tournier B, Jooste V, Chapusot C, Weijenberg MP, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2014 Jun 15;20(12):3261-71. doi: 10.1158/1078-0432.CCR-12-3734.

6.

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients.

Draht MX, Smits KM, Tournier B, Jooste V, Chapusot C, Carvalho B, Cleven AH, Derks S, Wouters KA, Belt EJ, Stockmann HB, Bril H, Weijenberg MP, van den Brandt PA, de Bruïne AP, Herman JG, Meijer GA, Piard F, Melotte V, van Engeland M.

Mol Oncol. 2014 May;8(3):679-88. doi: 10.1016/j.molonc.2014.01.011. Epub 2014 Feb 2.

7.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

8.

Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC.

Gilsing AM, Fransen F, de Kok TM, Goldbohm AR, Schouten LJ, de Bruïne AP, van Engeland M, van den Brandt PA, de Goeij AF, Weijenberg MP.

Carcinogenesis. 2013 Dec;34(12):2757-66. doi: 10.1093/carcin/bgt290. Epub 2013 Aug 27.

PMID:
23983135
9.

A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis.

Simons CC, Hughes LA, Smits KM, Khalid-de Bakker CA, de Bruïne AP, Carvalho B, Meijer GA, Schouten LJ, van den Brandt PA, Weijenberg MP, van Engeland M.

Ann Oncol. 2013 Aug;24(8):2048-56. doi: 10.1093/annonc/mdt076. Epub 2013 Mar 26.

PMID:
23532114
10.

Chromosome 5q loss in colorectal flat adenomas.

Voorham QJ, Carvalho B, Spiertz AJ, van Grieken NC, Mongera S, Rondagh EJ, van de Wiel MA, Jordanova ES, Ylstra B, Kliment M, Grabsch H, Rembacken BJ, Arai T, de Bruïne AP, Sanduleanu S, Quirke P, Mulder CJ, van Engeland M, Meijer GA.

Clin Cancer Res. 2012 Sep 1;18(17):4560-9. Epub 2012 Jul 3. Erratum in: Clin Cancer Res. 2013 May 15;19(10):2787.

11.

Nonpolypoid colorectal neoplasms: gender differences in prevalence and malignant potential.

Rondagh EJ, Masclee AA, van der Valk ME, Winkens B, de Bruïne AP, Kaltenbach T, Soetikno RM, Sanduleanu S.

Scand J Gastroenterol. 2012 Jan;47(1):80-8. doi: 10.3109/00365521.2011.638395. Epub 2011 Dec 8.

PMID:
22149943
12.

Endoscopic red flags for the detection of high-risk serrated polyps: an observational study.

Rondagh EJ, Masclee AA, Bouwens MW, Winkens B, Riedl RG, de Bruïne AP, de Ridder R, Kaltenbach T, Soetikno RM, Sanduleanu S.

Endoscopy. 2011 Dec;43(12):1052-8. doi: 10.1055/s-0030-1256770. Epub 2011 Oct 4.

PMID:
21971921
13.

Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.

Khalid-de Bakker CA, Jonkers DM, Sanduleanu S, de Bruïne AP, Meijer GA, Janssen JB, van Engeland M, Stockbrügger RW, Masclee AA.

Cancer Prev Res (Phila). 2011 Oct;4(10):1563-71. doi: 10.1158/1940-6207.CAPR-11-0076. Epub 2011 Jul 12.

14.

Body size, physical activity and risk of colorectal cancer with or without the CpG island methylator phenotype (CIMP).

Hughes LA, Simons CC, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruïne AP, van Engeland M, Weijenberg MP.

PLoS One. 2011 Apr 5;6(4):e18571. doi: 10.1371/journal.pone.0018571.

15.

Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer.

Lambregts DM, Beets GL, Maas M, Kessels AG, Bakers FC, Cappendijk VC, Engelen SM, Lahaye MJ, de Bruïne AP, Lammering G, Leiner T, Verwoerd JL, Wildberger JE, Beets-Tan RG.

Ann Surg. 2011 Mar;253(3):539-45. doi: 10.1097/SLA.0b013e31820b01f1.

PMID:
21239980
16.

Loss of SerpinA5 protein expression is associated with advanced-stage serous ovarian tumors.

Bijsmans IT, Smits KM, de Graeff P, Wisman GB, van der Zee AG, Slangen BF, de Bruïne AP, van Engeland M, Sieben NL, Van de Vijver KK.

Mod Pathol. 2011 Mar;24(3):463-70. doi: 10.1038/modpathol.2010.214. Epub 2010 Nov 19.

17.

Dietary methyl donors, methyl metabolizing enzymes, and epigenetic regulators: diet-gene interactions and promoter CpG island hypermethylation in colorectal cancer.

de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, van Engeland M, Weijenberg MP.

Cancer Causes Control. 2011 Jan;22(1):1-12. doi: 10.1007/s10552-010-9659-6. Epub 2010 Oct 20.

18.

The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications.

Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruïne AP, Baldwin HS, van Engeland M.

FASEB J. 2010 Nov;24(11):4153-66. doi: 10.1096/fj.09-151464. Epub 2010 Jul 28. Review.

PMID:
20667976
19.

Absence of tumor invasion into pelvic structures in locally recurrent rectal cancer: prediction with preoperative MR imaging.

Dresen RC, Kusters M, Daniels-Gooszen AW, Cappendijk VC, Nieuwenhuijzen GA, Kessels AG, de Bruïne AP, Beets GL, Rutten HJ, Beets-Tan RG.

Radiology. 2010 Jul;256(1):143-50. doi: 10.1148/radiol.10090725.

PMID:
20574091
20.

Butyrate enemas improve intestinal anastomotic strength in a rat model.

Bloemen JG, Schreinemacher MH, de Bruine AP, Buurman WA, Bouvy ND, Dejong CH.

Dis Colon Rectum. 2010 Jul;53(7):1069-75. doi: 10.1007/DCR.0b013e3181d881b7.

PMID:
20551761
21.

Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study.

Hughes LA, van den Brandt PA, Goldbohm RA, de Goeij AF, de Bruïne AP, van Engeland M, Weijenberg MP.

Int J Epidemiol. 2010 Oct;39(5):1333-44. doi: 10.1093/ije/dyq062. Epub 2010 Apr 28.

PMID:
20427463
22.

Human intestinal ischemia-reperfusion-induced inflammation characterized: experiences from a new translational model.

Grootjans J, Lenaerts K, Derikx JP, Matthijsen RA, de Bruïne AP, van Bijnen AA, van Dam RM, Dejong CH, Buurman WA.

Am J Pathol. 2010 May;176(5):2283-91. doi: 10.2353/ajpath.2010.091069. Epub 2010 Mar 26.

23.

VHL and HIF signalling in renal cell carcinogenesis.

Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruïne AP.

J Pathol. 2010 Jun;221(2):125-38. doi: 10.1002/path.2689. Review.

PMID:
20225241
24.

A new model to study intestinal ischemia-reperfusion damage in man.

Derikx JP, Matthijsen RA, de Bruïne AP, van Dam RM, Buurman WA, Dejong CH.

J Surg Res. 2011 Apr;166(2):222-6. doi: 10.1016/j.jss.2009.09.046. Epub 2009 Oct 22.

PMID:
20070978
25.

Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.

van Vlodrop IJ, Baldewijns MM, Smits KM, Schouten LJ, van Neste L, van Criekinge W, van Poppel H, Lerut E, Schuebel KE, Ahuja N, Herman JG, de Bruïne AP, van Engeland M.

Am J Pathol. 2010 Feb;176(2):575-84. doi: 10.2353/ajpath.2010.090442. Epub 2009 Dec 30.

26.

Localization of the lipopolysaccharide recognition complex in the human healthy and inflamed premature and adult gut.

Wolfs TG, Derikx JP, Hodin CM, Vanderlocht J, Driessen A, de Bruïne AP, Bevins CL, Lasitschka F, Gassler N, van Gemert WG, Buurman WA.

Inflamm Bowel Dis. 2010 Jan;16(1):68-75. doi: 10.1002/ibd.20995.

PMID:
20014022
27.

Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms.

Hughes LA, van den Brandt PA, de Bruïne AP, Wouters KA, Hulsmans S, Spiertz A, Goldbohm RA, de Goeij AF, Herman JG, Weijenberg MP, van Engeland M.

PLoS One. 2009 Nov 23;4(11):e7951. doi: 10.1371/journal.pone.0007951.

28.

Prognostic role of vasculogenic mimicry in colorectal cancer.

Baeten CI, Hillen F, Pauwels P, de Bruine AP, Baeten CG.

Dis Colon Rectum. 2009 Dec;52(12):2028-35. doi: 10.1007/DCR.0b013e3181beb4ff.

PMID:
19934926
29.

Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.

de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, Weijenberg MP, van Engeland M.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3086-96. doi: 10.1158/1055-9965.EPI-09-0289. Epub 2009 Oct 20.

30.

Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.

Baldewijns MM, van Vlodrop IJ, Smits KM, Vermeulen PB, Van den Eynden GG, Schot F, Roskams T, van Poppel H, van Engeland M, de Bruïne AP.

Cell Oncol. 2009;31(5):371-82. doi: 10.3233/CLO-2009-0482.

31.

Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies.

Troyer DA, Lucia MS, de Bruïne AP, Mendez-Meza R, Baldewijns MM, Dunscomb N, Van Engeland M, McAskill T, Bierau K, Louwagie J, Bigley JW.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2717-22. doi: 10.1158/1055-9965.EPI-09-0068. Epub 2009 Sep 15.

32.

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis.

van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, de Bruyn EM, Sleddens HF, Derkx P, Rivière J, Dannenberg H, Petri BJ, Komminoth P, Pacak K, Hop WC, Pollard PJ, Mannelli M, Bayley JP, Perren A, Niemann S, Verhofstad AA, de Bruïne AP, Maher ER, Tissier F, Méatchi T, Badoual C, Bertherat J, Amar L, Alataki D, Van Marck E, Ferrau F, François J, de Herder WW, Peeters MP, van Linge A, Lenders JW, Gimenez-Roqueplo AP, de Krijger RR, Dinjens WN.

Lancet Oncol. 2009 Aug;10(8):764-71. doi: 10.1016/S1470-2045(09)70164-0. Epub 2009 Jul 1.

33.

N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.

Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.

J Natl Cancer Inst. 2009 Jul 1;101(13):916-27. doi: 10.1093/jnci/djp131. Epub 2009 Jun 17.

PMID:
19535783
34.

GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer.

Hellebrekers DM, Lentjes MH, van den Bosch SM, Melotte V, Wouters KA, Daenen KL, Smits KM, Akiyama Y, Yuasa Y, Sanduleanu S, Khalid-de Bakker CA, Jonkers D, Weijenberg MP, Louwagie J, van Criekinge W, Carvalho B, Meijer GA, Baylin SB, Herman JG, de Bruïne AP, van Engeland M.

Clin Cancer Res. 2009 Jun 15;15(12):3990-7. doi: 10.1158/1078-0432.CCR-09-0055. Epub 2009 Jun 9.

35.

Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer.

Glöckner SC, Dhir M, Yi JM, McGarvey KE, Van Neste L, Louwagie J, Chan TA, Kleeberger W, de Bruïne AP, Smits KM, Khalid-de Bakker CA, Jonkers DM, Stockbrügger RW, Meijer GA, Oort FA, Iacobuzio-Donahue C, Bierau K, Herman JG, Baylin SB, Van Engeland M, Schuebel KE, Ahuja N.

Cancer Res. 2009 Jun 1;69(11):4691-9. doi: 10.1158/0008-5472.CAN-08-0142. Epub 2009 May 12.

36.

Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes?

Lahaye MJ, Beets GL, Engelen SM, Kessels AG, de Bruïne AP, Kwee HW, van Engelshoven JM, van de Velde CJ, Beets-Tan RG.

Radiology. 2009 Jul;252(1):81-91. doi: 10.1148/radiol.2521081364. Epub 2009 Apr 29.

PMID:
19403848
37.

Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part I. Are we able to predict tumor confined to the rectal wall?

Dresen RC, Beets GL, Rutten HJ, Engelen SM, Lahaye MJ, Vliegen RF, de Bruïne AP, Kessels AG, Lammering G, Beets-Tan RG.

Radiology. 2009 Jul;252(1):71-80. doi: 10.1148/radiol.2521081200. Epub 2009 Apr 29.

PMID:
19403847
38.

Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21.

Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruïne AP, Herman JG, van Engeland M.

Carcinogenesis. 2009 Jun;30(6):1041-8. doi: 10.1093/carcin/bgp073. Epub 2009 Mar 27.

PMID:
19329758
39.

MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.

de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den Brandt PA, de Bruïne AP, van Engeland M.

Ann Oncol. 2009 Jul;20(7):1216-22. doi: 10.1093/annonc/mdn782. Epub 2009 Jan 22.

PMID:
19164452
40.

A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity.

Baldewijns MM, Roskams T, Ballet V, Van den Eynden GG, Van Laere SJ, Van der Auwera I, Lerut E, De Bruïne AP, Thijssen VL, Vermeulen PB, van Poppel H.

BJU Int. 2009 Jun;103(12):1626-31. doi: 10.1111/j.1464-410X.2008.08272.x. Epub 2009 Jan 12.

41.

Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response.

Smits KM, Cleven AH, Weijenberg MP, Hughes LA, Herman JG, de Bruïne AP, van Engeland M.

Pharmacogenomics. 2008 Dec;9(12):1903-16. doi: 10.2217/14622416.9.12.1903. Review.

PMID:
19072647
42.

Rapid reversal of human intestinal ischemia-reperfusion induced damage by shedding of injured enterocytes and reepithelialisation.

Derikx JP, Matthijsen RA, de Bruïne AP, van Bijnen AA, Heineman E, van Dam RM, Dejong CH, Buurman WA.

PLoS One. 2008;3(10):e3428. doi: 10.1371/journal.pone.0003428. Epub 2008 Oct 17.

43.

An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1.

Hanigan CL, Van Engeland M, De Bruine AP, Wouters KA, Weijenberg MP, Eshleman JR, Herman JG.

Gastroenterology. 2008 Nov;135(5):1654-1664.e2. doi: 10.1053/j.gastro.2008.07.078. Epub 2008 Aug 7.

PMID:
18834886
44.

Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis.

Cleven AH, Wouters BG, Schutte B, Spiertz AJ, van Engeland M, de Bruïne AP.

Br J Cancer. 2008 Sep 2;99(5):727-33. doi: 10.1038/sj.bjc.6604547. Epub 2008 Aug 19.

45.

Associations of dietary methyl donor intake with MLH1 promoter hypermethylation and related molecular phenotypes in sporadic colorectal cancer.

de Vogel S, Bongaerts BW, Wouters KA, Kester AD, Schouten LJ, de Goeij AF, de Bruïne AP, Goldbohm RA, van den Brandt PA, van Engeland M, Weijenberg MP.

Carcinogenesis. 2008 Sep;29(9):1765-73. doi: 10.1093/carcin/bgn074. Epub 2008 Mar 13.

PMID:
18339680
46.

Mesorectal fascia invasion after neoadjuvant chemotherapy and radiation therapy for locally advanced rectal cancer: accuracy of MR imaging for prediction.

Vliegen RF, Beets GL, Lammering G, Dresen RC, Rutten HJ, Kessels AG, Oei TK, de Bruïne AP, van Engelshoven JM, Beets-Tan RG.

Radiology. 2008 Feb;246(2):454-62. doi: 10.1148/radiol.2462070042.

PMID:
18227541
47.

USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria.

Lahaye MJ, Engelen SM, Kessels AG, de Bruïne AP, von Meyenfeldt MF, van Engelshoven JM, van de Velde CJ, Beets GL, Beets-Tan RG.

Radiology. 2008 Mar;246(3):804-11. doi: 10.1148/radiol.2463070221. Epub 2008 Jan 14.

PMID:
18195379
48.

Genetics and epigenetics of renal cell cancer.

Baldewijns MM, van Vlodrop IJ, Schouten LJ, Soetekouw PM, de Bruïne AP, van Engeland M.

Biochim Biophys Acta. 2008 Apr;1785(2):133-55. doi: 10.1016/j.bbcan.2007.12.002. Epub 2007 Dec 15. Review.

PMID:
18187049
49.

Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.

Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG, Weijenberg MP, de Bruïne AP, Meijer GA, van Engeland M.

Carcinogenesis. 2008 Feb;29(2):434-9. Epub 2007 Nov 28.

PMID:
18048385
50.

Dietary fat and risk of colon and rectal cancer with aberrant MLH1 expression, APC or KRAS genes.

Weijenberg MP, Lüchtenborg M, de Goeij AF, Brink M, van Muijen GN, de Bruïne AP, Goldbohm RA, van den Brandt PA.

Cancer Causes Control. 2007 Oct;18(8):865-79. Epub 2007 Jul 18.

Supplemental Content

Loading ...
Support Center